Video

Dr. Abramson on Safety and Efficacy of Liso-Cel in Relapsed/Refractory Large B-Cell Lymphoma

Author(s):

Jeremy Abramson, MD
Conference|ASH Annual Meeting and Exposition

Jeremy S. Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses the pivotal safety and efficacy results from phase I TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory large B-cell lymphoma.

Jeremy S. Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses the pivotal safety and efficacy results from phase I TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory large B-cell lymphoma.

<<< View more from the 2019 ASH Annual Meeting

Related Videos
J. Bradley Elder, MD
Rimas V. Lukas, MD
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
Minoo Battiwalla, MD, MS
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Related Content
peterschreiber.media– stock.adobe.com
November 23rd 2024

Vorasidenib Shows Consistent Efficacy With Manageable Safety in IDH1/2-Mutant Diffuse Glioma

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
October 10th 2022

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Michael Badruddoja, MD
November 23rd 2024

NanO2 Plus Radiation/Temozolomide Is Under Exploration in Newly Diagnosed Glioblastoma

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL
July 28th 2022

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL

Syed Abbas Ali, MBBS
November 22nd 2024

Bispecific Antibodies and CAR T-Cell Therapies Continue to Reshape Myeloma Treatment Landscape

Urothelial Cancer
November 16th 2024

Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment